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Abstract
Background: Glucagon-like peptide-1 (GLP-1) is a hormone predominately synthesized and secreted by intestinal
L-cells. GLP-1 modulates multiple cellular functions and its receptor agonists are now used clinically for diabetic
treatment. Interestingly, preclinical and clinical evidence suggests that GLP-1 agonists produce beneficial effects on
dysfunctional hearts via acting on myocardial GLP-1 receptors. As the effects of GLP-1 on myocyte
electrophysiology are largely unknown, this study was to assess if GLP-1 could affect the cardiac voltage-gated L-
type Ca
2+ current (ICa).
Methods: The whole-cell patch clamp method was used to record ICa and action potentials in enzymatically
isolated cardiomyocytes from adult canine left ventricles.
Results: Extracellular perfusion of GLP-1 (7-36 amide) at 5 nM increased ICa by 23 ± 8% (p < 0.05, n = 7).
Simultaneous bath perfusion of 5 nM GLP-1 plus 100 nM Exendin (9-39), a GLP-1 receptor antagonist, was unable
to block the GLP-1-induced increase in ICa; however, the increase in ICa was abolished if Exendin (9-39) was pre-
applied 5 min prior to GLP-1 administration. Intracellular dialysis with a protein kinase A inhibitor also blocked the
GLP-1-enhanced ICa. In addition, GLP-1 at 5 nM prolonged the durations of the action potentials by 128 ± 36 ms (p
< 0.01) and 199 ± 76 ms (p < 0.05) at 50% and 90% repolarization (n = 6), respectively.
Conclusions: Our data demonstrate that GLP-1 enhances ICa in canine cardiomyocytes. The enhancement of ICa is
likely via the cAMP-dependent protein kinase A mechanism and may contribute, at least partially, to the
prolongation of the action potential duration.
Background
Glucagon-like peptide-1 (GLP-1) is one of the transcrip-
tion products from the proglucagon gene. GLP-1 is a
peptide hormone predominately produced by intestinal
endocrine L-cells. GLP-1 has two major isoforms (7-36
amide and 7-37) which are among the most potent sti-
mulators of glucose-dependent insulin secretion. Both
peptides are considered equipotent in terms of their bio-
logical activity[1,2]. GLP-1 stimulates glucose-dependent
insulin secretion and insulin biosynthesis and inhibits
glucagon secretion, gastric emptying, and food intake.
The N-terminal degradation of GLP-1 by dipeptidyl
peptidase-4 (DPP-4)-mediated cleavage at the position 2
alanine modifies its biological activity[3].
GLP-1 modulates multiple cellular functions believably
via acting on GLP-1 receptors (GLP-1Rs)[4], which are
expressed in the human pancreas, heart, lung, kidney,
stomach and brain[5]. Due to the multiple beneficial
effects of GLP-1R agonists in the treatment of diabetes
mellitus including weight loss, pharmaceutical compa-
nies have developed and introduced GLP-1R agonists as
a treatment option for patients with type 2 diabetes mel-
litus (e.g. Byetta™ (exenatide) and Victoza™ (liraglu-
tide)). Various cardiovascular effects of GLP-1 have
been reported. GLP-1 infusion improves glucose uptake
[6] and metabolism[7], as well as cardiac function[6]
and hemodynamics[8-10] in different species, including
in humans[11]. In addition, GLP-1 infusion reduced
infarct size in a rodent model of ischemia with no effect
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size in an open-chest, anesthetized porcine model of
ischemia[5]. Furthermore, GLP-1R knockout mice
(GLP-1R
-/
-) have lower heart rate and blood pressure
with an increase in cardiac mass[14]. In clinical studies
using liraglutide (Victoza™), a GLP-1R agonist, a con-
sistent decrease in blood pressure and a reduction of
cardiovascular risk markers were observed in a cohort
of over 5000 patients[15].
In pancreatic b-cells, GLP-1 inhibits ATP-dependent
K
+ channels via the cAMP-mediated PKA pathway
[16-19]. The effects of GLP-1 on myocardium observed
in several studies are potentially via its G protein-
coupled receptors[10,20]. Recently, a new glucagon-like
peptide isolated from the intestine of the eel, Anguilla
japonica[21] with a structure similar to that of oxynto-
modulins has shown an inotropic effect via stimulation
of Ca
2+ influx and a chronotropic effect independent of
extracellular Ca
2+. In addition, GLP-1 and glucose-
dependent insulinotropic polypeptide can enhance b-cell
cytoplasmic Ca
2+ oscillation and increase insulin secre-
tion via activation of cAMP-triggered cascades[22,23].
However, the effects of GLP-1 on myocyte electrophy-
siology have not been carefully assessed. Therefore, in
the present study, we investigated the effects of GLP-1
on the voltage-gated L-type Ca
2+ channel in isolated
canine left ventricular myocytes.
Methods
The study was designed and conducted in accordance
with the Guide for the Care and Use of Laboratory Ani-
mals [Department of Health and Human Services Publi-
cation No. (NIH) 85-23, Revised 1996]. The animal
protocol was approved by the Institutional Animal Care
and Use Committee of the Physiological Research
Laboratories of Medtronic, Inc.
Isolation of canine left ventricular myocytes
Single left ventricular myocytes were enzymatically iso-
lated from adult canine hearts with a body weight of 30
to 33 kg (n = 13) by the methods described previously
[24]. Briefly, left ventricular heart tissue was rapidly
excised from canine hearts. Several tissue pieces weigh-
ing 3-5 grams each were harvested from the left ventri-
cle and immediately placed in ice-cold Ca
2+-free
dissection buffer ("cardioplegia”) solution containing
(mM): NaCl 140, KCl 5.4, MgCl2 1.2, HEPES 5, glucose
5.5, and 2,3-butanedione monoxime 30, pH 7.4. Tissue
pieces were rinsed twice by the dissection solution sup-
plemented with antibiotics and cut into small pieces (~1
mm
3) with sharp scissors. Digestion buffer solution was
aspirated and replaced with a Ca
2+-free enzymatic solu-
tion containing 0.1% trypsin, 0.075% collagenase type II,
0.05% cyaluronidase, and 0.025% elastase. Tissue was
incubated in Ca
2+-free enzymatic solution at 4°C over-
night and then subjected to a 37°C digestion procedure.
During 37°C digestion, Ca
2+-free enzymatic solution
containing trypsin was gradually replaced with another
enzymatic solution containing 0.1 mM of Ca
2+, 0.075%
collagenase, 0.1% soybean trypsin inhibitor, and 0.2%
bovine serum albumin. The tissues were agitated in a
heated shaker (~300 rpm at 37°C) for several 15-min
intervals. After agitation, the tissue was triturated about
1 5 - 2 0t i m e sw i t ha1 0m lp i p e t t e .T h et i s s u ew a s
allowed to settle, supernatants were removed, and a
fresh aliquot of enzymatic solution was added. The first
two supernatants containing mostly cell debris were
aspirated and discarded. The subsequent supernatants
containing liberated cells were collected into centrifuge
tubes, where a cell culture media with 20% fetal bovine
serum was added. Collected cell suspensions were cen-
trifuged for 5 min at 300 rpm and the resulting superna-
tant was discarded. The myocyte pellets were
resuspended in a HEPES-buffered cell culture media.
Yields from this procedure were about 50% of Ca
2+-tol-
erant myocytes. Quiescent, rod-shaped ventricular myo-
cytes with clear striations were chosen for patches to
study their electrophysiology and GLP-1 effects.
Electrophysiological recordings
After dissociation, a small amount (30 μl) of the med-
ium solution with myocytes was transported to a cham-
ber mounted on the stage of a Nikon microscope
(Nikon, Japan). The chamber was continuously super-
fused (~1.0 ml/min) with Tyrode solution. The whole-
cell configuration of the patch-clamp technique was
applied. Briefly, glass electrodes (World Precision Instru-
ments, Sarasota, FL, USA) with 1 to 3 MΩ resistance
were connected via an Ag-AgCl wire to an Axopatch
200A amplifier interfaced with a DigiData-1320 acquisi-
tion system (Molecular Devices, Inc., Sunnyvale, CA,
USA). After forming a conventional “gigaohm” seal,
electrode capacitance was compensated. Additional suc-
tion ruptured the patched membrane and formed the
whole-cell configuration. Cell membrane capacitance
(Cm) was routinely recorded from each patched cell
with the pCLAMP program (version 9.2, Molecular
Devices, Inc., Sunnyvale, CA, USA). Ca
2+ currents were
recorded with the protocols similar to those previously
described[25]. Action potential (AP) was evoked and
recorded with the whole-cell current-clamp method[26].
Chemicals and solutions
GLP-1 and its receptor inhibitor Exendin (9-39) were
purchased from Bachem Americas, Inc. (Torrance, CA,
USA). GLP-1 (7-36 amide) was tested at concentrations
ranging from 0.05 nM to 5 nM for its effect on isolated
canine left ventricular myocytes. The effects of Exendin
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inhibitor 4-25 fragment (Sigma, St. Louis, MO, USA)
were also assessed in isolated single cardiomyocytes
with or without GLP-1 treatment.
For recording Ca
2+ currents, the bath solution con-
tained (in mM): NaCl 140, CsCl 5, MgCl2 1, CaCl2 1.8,
glucose 5, and HEPES 10 (pH 7.4 with HCl). The pip-
ette solution contained (in mM): CsCl 100, CsOH 40,
MgCl2 1, CaCl2 1, EGTA 11, Mg-ATP 5, and HEPES 10
(pH 7.3 with CsOH). ATP and all other chemicals used
in this study were obtained from Sigma Aldrich (St.
Louis, MO, USA). The bath solution for recording APs
contained (mM): NaCl 140; KCl 5.4; CaCl2 1.8; MgCl2 1;
D-glucose 5; HEPES 10 (pH adjusted to 7.4 with
NaOH). The pipette solution for recording APs con-
tained (mM): K-glutamate 130; KCl 15; NaCl 5; MgATP
5; MgCl2 1; EGTA 5; CaCl2 1; HEPES 10 (pH adjusted
to 7.2 with KOH). A perfusion system was used to
change the extracellular solution. Data were collected
with pCLAMP (version 9.2, Axon Instruments, CA,
USA). All experiments were conducted at room tem-
perature (~22°C).
Data analysis
Peak ICa was measured in the presence or absence of
GLP-1 or other chemical compounds. The parameters
o fA P sw e r ea n a l y z e db yu s i n gt h em e t h o d ss i m i l a rt o
those described in a previous report[26]. The maximal
effects of GLP-1 on ICa and APs were used in the table
and figures. All data were presented as mean ± standard
error of the mean unless otherwise stated. The Student’s
t-test and ANOVA were applied for statistical analysis
as appropriate. Differences were considered significant if
p < 0.05.
Results
Effects of GLP-1 and Exendin (9-39) on L-type Ca
2+
currents
Extracellular perfusion of 5 nM GLP-1 (7-36 amide)
solution gradually increased the peak currents and
reached the maximal effects around 10 to 15 min. Fig-
ure 1A shows the representative traces in the presence
or absence of 5 nM GLP-1. The enhancement effect of
GLP-1 on ICa was washable upon washing away of the
compound. While GLP-1 at 5 nM significantly increased
the peak currents (Fig. 1B), the current-voltage relation-
ship of the activation was not altered and the kinetics of
the activation and the steady-state inactivation of ICa
slightly shifted, but not significantly, to the hyperpolariz-
ing direction in the presence of 5 nM GLP-1 (Fig. 1C
and 1D, n = 7).
To determine whether the GLP-1-induced enhance-
ment of ICa was via the activation of membrane GLP-
1Rs, the GLP-1R inhibitor Exendin (9-39) was added to
the GLP-1 solution. The non-mammalian peptide, Exen-
din (9-39 amide), is a specific and competitive antago-
nist of GLP-1Rs. As Exendin (9-39) has lower binding
affinity to GLP-1Rs, 100 nM Exendin (9-39), at a con-
centration of 20 times higher than that of GLP-1, plus 5
nM GLP-1, was perfused to the canine left ventricular
myocytes. Interestingly, Exendin (9-39) at 100 nM was
unable to block the GLP-1-induced enhancement of ICa
(Fig. 2A and 2B). These results suggest that when GLP-
1 and Exendin (9-39) were applied together at the same
time, GLP-1 could activate GLP-1Rs due to its higher
affinity for GLP-1 receptors. After the activation of
GLP-1Rs, the enhancement of ICa by GLP-1 was not
blocked by 100 nM Exendin (9-39) because the activa-
tion process was already beyond the receptor stage. To
test this hypothesis, we administered 100 nM Exendin
(9-39) 5 min prior to GLP-1. Figure 2C and 2D clearly
shows that Exendin (9-39) alone did not significantly
alter the currents, but the enhancement of ICa by 5 nM
GLP-1 was abolished by pre-administration of 100 nM
Exendin (9-39).
Protein kinase A and GLP-1-induced enhancement of Ca
2+
currents
To determine whether the GLP-1-induced enhancement
of ICa was via activation of the cAMP/PKA pathway, the
PKA inhibitor (PKA-I fragment 4-25 amide, 5 μM) was
added to the electrode solution. After forming a whole-
cell configuration, ICa was immediately recorded (Fig. 3,
Control). Each cell was dialyzed for 20 min with PKA-I
and ICa was recorded. The peak currents recorded at 20
min after intracellular PKA-I dialysis were not signifi-
cantly changed (Fig. 3, PKA-I). Extracellular perfusion of
5 nM GLP-1 for 15 min did not induce a significant
increase in ICa (Fig. 3, PKA-I+GLP-1). Compared with
the significant increase in ICa of the cardiomyocytes
t r e a t e dw i t h5n MG L P - 1a l o n e( 2 3±8 % ,n=7 ,p <
0.05, Fig. 1B), ICa in the myocytes with intracellular dia-
lysis of PKA-I was not significantly altered by the same
c o n c e n t r a t i o no fG L P - 1( 8±1 3 % ,n=5 ,p > 0.05, Fig.
3, PKA-I+GLP-1). This result suggests that GLP-1-
induced enhancement of ICa was most likely via the acti-
vation of the PKA pathway.
GLP-1-induced prolongation of action potential duration
As L-type Ca
2+ currents can affect the plateau of a car-
diac action potential (AP) and as GLP-1 could enhance
ICa, we next investigated the effects of GLP-1 on the AP
duration (APD). Figure 4A shows that extracellular per-
fusion of 5 nM GLP-1 gradually prolonged the APDs of
the patched cardiomyocyte. The prolongation effect was
initiated within 2 min after GLP-1 perfusion and
reached the maximal level around 10 min. The GLP-1-
induced APD prolongation was recoverable after
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The durations of the APs measured at 50% and 90%
repolarization were significantly prolonged in the pre-
sence of 5 nM GLP-1 (Fig. 4B and Table 1). Other AP
parameters, such as amplitude, threshold, and maximum
upstroke velocity of AP, were not significantly altered in
the presence of 5 nM GLP-1. The APD prolongations
showed a concentration-dependent trend. The delta
prolongations were 24.8 ± 11.5 ms and 25.7 ± 15.7 ms
for 0.05 nM GLP-1, and 42.2 ± 25.1 ms and 48.5 ± 25.2
ms for 0.5 nM GLP-1 measured at 50% and 90% repo-
larization, respectively, but these changes did not reach
statistical significance at both concentrations (p > 0.05,
n = 6).
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Figure 1 Effects of GLP-1 on voltage-gated L-type Ca
2+ currents in isolated canine left ventricular myocytes. The representative traces of
ICa in the absence (Control and Washout) and presence (GLP-1) of 5 nM GLP-1 are shown in panel A. The currents were evoked by the
depolarizing pulses from the holding potential of -40 mV to 0 mV every 10 s. The current traces represented the ICa recorded at the times just
before GLP-1 (Control), 12 min after GLP-1 perfusion (GLP-1), and 10 min after washout of GLP-1 (Washout). Panel B shows the average increase
in the peak ICa in the presence of 5 nM GLP-1 (n = 7, p < 0.01). Panel C shows the effects of 5 nM GLP-1 on the current-voltage relationship of
ICa recorded from a representative myocyte in the presence (solid circle) and absence (open circle) of 5 nM GLP-1. The normalized currents were
calculated as the ratio of the peak ICa,GLP-1 to the maximal peak ICa,Control. The voltage protocol was composed of a group of pulses from -50 mV
to 50 mV with 10 mV increments every 10 s. The membrane holding potential was -40 mV. The inset in the panel C shows the activation curves
in the presence (solid circle) and absence (open circle) of 5 nM GLP-1. Panel D shows the steady-state inactivation of L-type Ca
2+ currents (n =
7) in the presence (solid circle) and absence (open circle) of 5 nM GLP-1. The voltage protocol had double pulses consisting of a 200-ms test
pulse to 0 mV following a 500-ms conditioning pulse varying from -60 to 20 mV in 10-mV increments every 10 ms with membrane holding
potential of -40 mV. Normalized inactivation data were fit to a Boltzmann equation (solid lines): y = 1/{1 + exp[(V + V0.5)/K]}, where V0.5 is the
voltage at which y = 0.5 and K is the slope factor.
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The main finding in this study is that GLP-1 (7-36
amide) can enhance voltage-gated L-type Ca
2+ currents
in isolated canine left ventricular myocytes. The GLP-1-
induced enhancement of Ca
2+ currents was significantly
attenuated in the presence of the GLP-1R inhibitor
Exendin (9-39) (Fig. 2) or by intracellular dialysis with
the PKA inhibitor, PKA-I fragment 4-25 (Fig. 3). The
effect of GLP-1 on ICa observed in this study may help
to interpret the chronotropic effect of GLP-1 in vivo
[8-10], perhaps via the modulation of Ca
2+ channels of
sinoatrial node cells.
GLP-1 receptors in cardiomyocytes
The existence of GLP-1Rs has been demonstrated in
many human organs and tissues, including the pancreas,
heart, lung, kidney, stomach and brain [5]. The data
from the current study suggest that canine left
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Figure 2 Effects of the GLP-1R inhibitor Exendin (9-39) on the GLP-1-induced enhancement of L-type Ca
2+ currents in isolated canine
left ventricular myocytes. A, The time course of the extracellular perfusion of Exendin (9-39, 100 nM) plus GLP-1 (5 nM) is shown. The GLP-1-
induced enhancement of Ca
2+ currents was not blocked by Exendin (9-39), even after washout and reperfusion of these two compounds. The
currents were evoked by the depolarizing pulses from a holding potential of -40 mV to 0 mV every 10 s. C, control; E&G, Exendin (9-39) + GLP-1;
W, washout. B, Compared to control, the average increase in peak ICa was statistically significant in the presence of Exendin (9-39) plus GLP-1 (n
=6 ,p < 0.05). Panel C shows the time course of ICa for control, the extracellular perfusion of 100 nM Exendin (9-39) alone (Exendin (9-39)) and
Exendin (9-39) plus 5 nM GLP-1 (GLP-1), and washout (W). The currents were evoked by the pulses depolarizing from holding potential of -40
mV to 0 mV every 10 s. D, The averaged data show that 100 nM Exendin (9-39) applied 5 min ahead of GLP-1 (5 nM) perfusion abolished the
GLP-1-induced enhancement of ICa (n = 5, p > 0.05).
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because GLP-1 enhanced ICa and prolonged APD, and
also because the GLP-1-induced enhancement of ICa
was blocked by specific GLP-1R inhibitor Exendin
(9-39). However, the concentration of Exendin (9-39)
required to block the GLP-1 effects was relatively high,
and the antagonist was also required prior to adminis-
tration of GLP-1 (Fig. 2). This suggests that compared
with GLP-1, Exendin (9-39) is a competitive inhibitor
with a lower GLP-1R binding affinity and slower binding
kinetics at the cardiac GLP-1R. There is a possibility
that the effects of GLP-1 on myocyte electrophysiology
is via a GLP-1R-independent mechanism. However,
since no report so far has shown that GLP-1 can affect
cellular function via a non-receptor approach, and since
pre-administration of Exendin (9-39) abolished the
increase in ICa subsequent to GLP-1 administration, we
believe that a receptor-independent mechanism of the
GLP-1-induced enhancement of ICa is most unlikely.
GLP-1 and the cAMP/PKA pathway
Voltage-gated L-type Ca
2+ currents influence the mor-
phology of cardiac action potential, especially the pla-
teau phase, and are also critical for excitation-
contraction coupling in the heart. Stimulation of the
cardiac b-adrenergic receptor increases Ca
2+ influx
through the voltage-gated L-type Ca
2+ channel[27]. The
cardiac b-adrenergic receptor is coupled to an intracel-
lular signaling cascade via the stimulatory G protein
(Gs) which can activate the cAMP-dependent PKA sys-
tem and enhance Ca
2+ channel phosphorylation. In car-
diomyocytes, the PKA-dependent phosphorylation of L-
type Ca
2+ channels increases ICa[27-29]. In the current
study, we found that the GLP-1-induced increase in ICa
was abolished by intracellular dialysis of a PKA inhibitor
(PKA-I fragment 4-25). This result suggests that GLP-1
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adenyl cyclase complex to enhance cAMP production.
Increase in intracellular cAMP activates PKA and then
enhances Ca
2+ channel phosphorylation. Phosphorylated
Ca
2+ channels increase their open probability when they
are activated by voltage change. This is why the GLP-1-
induced enhancement of ICa was blocked by PKA-I.
These results are along with the findings in the previous
studies in rodent cardiomyocytes that GLP-1 or the
GLP-1R agonist liraglutide significantly increased intra-
cellular cAMP, which was abolished by the GLP-1R
antagonist Exendin (9-39)[13,30]. Also, in the pancreatic
b-cell, GLP-1 enhances cytoplasmic Ca
2+ oscillation and
insulin secretion via activation of cAMP cascades[22,23].
T h ee f f e c t so fG L P - 1o nI Ca are most likely via the
activation of the GLP-1R and then the cAMP-dependent
PKA pathway. Activation of the PKA pathway is widely
recognized as a key intracellular signaling mechanism in
ischemic and pharmacological preconditioning. Subse-
quent cardioprotection of the PKA system may be bene-
ficial in both treating/preventing ischemic damage, as
well as apoptosis in heart failure. In studies by Bose et
al, it has been shown that GLP-1 administration can
reduce ischemia-reperfusion injury in part via activation
of PKA, as well as via activation of other pro-survival
kinases, and can be blocked by PKA inhibitors and inhi-
bitors of pro-survival kinases[12,31,32]. One of the lim-
itations in our experiments is that we did not directly
measure intracellular cAMP contents with or without
GLP-1 or GLP-1 plus a blocker of GLP-1R. However,
one previous study has shown that GLP-1 at 10 nM
doubled intracellular cAMP content in rat cardiac myo-
cytes[13]. The GLP-1R agonist liraglutide at 100 nM sig-
nificantly increased the level of intracellular cAMP in
mouse cardiomyocytes and this increase was abolished
by the GLP-1R antagonist Exendin (9-39)[30]. In addi-
tion, GLP-1 exerts cAMP/PKA-mediated insulinotropic
actions in endocrine tissues[19,33,34] and stimulates
adenylate cyclase to cause an increase in cAMP in pan-
creatic islet cells[34,35]. These results strongly suggest
that the cellular effects of GLP-1 involve the cAMP-
dependent PKA pathway and our data are consistent
with the previous findings.
The GLP-1-induced enhancement of ICa can trigger
intracellular Ca
2+ release. Elevation of intracellular Ca
2+
level can lead to an improvement of myocardial contrac-
tility. Several studies in pancreatic b-cells have shown
that GLP-1 synchronizes Ca
2+ and cAMP oscillations
[10,19,36] and such oscillations involves the ryanodine-
sensitive Ca
2+ store[22]. In addition, the experimental
evidence has shown that GLP-1 can augment Ca
2+
influx[37,38] and Ba
2+ currents[39] through L-type Ca
2+
channels via the cAMP-dependent PKA pathway in pan-
creatic b-cells. In addition, GLP-1 increases intracellular
cAMP content in adult rat cardiomyocytes[13].
Pharmacological effects of GLP-1
Our data demonstrate that GLP-1 can modulate cardio-
myocyte electrophysiology. However, GLP-1 (7-36
amide) in human plasma is normally less than 100 pM
[40-42]. GLP-1 administration at 5 nM to obtain a sig-
nificant effect on APs and ICa in this study is much
higher than a physiological level. Therefore, the effects
of GLP-1 on ICa and APs are most likely pharmacologi-
cal in this study. Various pharmacological concentra-
tions ranging from 10 to 100 nM of GLP-1 or GLP-1R
agonists have been tested in several previous studies. In
one clinical trial, GLP-1 (17 nmol) was infused to assess
its antidiabetogenic action[40]. GLP-1 (up to 100 nmol/
kg) was used to test its effects on insulin secretion, insu-
lin sensitivity, and glucose effectiveness in mice[43].
Moreover, 0.1 to 1000 nM GLP-1 was used to assess the
dose-dependent effect of GLP-1 on cAMP production
with an EC50 of 10 nM in rat cardiomyocytes[13] and
50 nM GLP-1 to study the role of L-type Ca
2+ channels
in mediating GLP-1-stimulated events in cultured pan-
creatic b-cell line INS-1[44]. As the GLP-1R agonists,
Byetta™ and Victoza™,h a v eb e e nu s e df o rt h et r e a t -
ment of patients with type II diabetes mellitus, the con-
centration of GLP-1 used in this study can have
pharmacological significance.
The beneficial effects of GLP-1 at various pharmacolo-
gical concentrations have been shown in several recent
animal studies. Chronic treatment with either GLP-1 or
AC3174, a peptide analogue with pharmacologic proper-
ties similar to the GLP-1R agonist exenatide, showed
Table 1 Effects of GLP-1 on action potentials of canine left ventricular cardiomyocytes
MHP mV AAP mV APT mV Vmax V/s APD50 ms APD90 ms
Control -80.2 ± 1.9 149.8 ± 4.6 -61.0 ± 2.4 126.6 ± 17.6 124.3 ± 24.4 236.1 ± 17.6
GLP-1 -84.2 ± 2.0 145.3 ± 4.5 -61.8 ± 1.6 120.8 ± 22.7 252.1 ± 30.5** 434.8 ± 79.2*
Washout -82.4 ± 2.3 142.2 ± 5.8 -62.4 ± 0.9 113.1 ± 25.5 120 ± 27..7 302.8 ± 66.9
Values are expressed as mean ± SEM (n = 6). GLP-1 (7-36 amide) at 5 nM was added to the bath solution. The data were collected at the times just before GLP-1
(Control), 10 to 15 min after GLP-1 perfusion (GLP-1), and 10 to 15 min after washout of GLP-1 (Washout). MHP, membrane holding potential before elicitation of
an action potential; AAP, amplitude of action potential; APT, threshold of initiation of an action potential; Vmax, maximum upstroke velocity of action potential;
APD, action potential duration measured at 50% (APD50) and 90% (APD90) of repolarization. *, p < 0.05; **, p < 0.01; versus control and washout.
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Page 7 of 9cardioprotective effects and improved cardiac function,
cardiac remodeling, insulin sensitivity, and exercise
capacity in myocardial infarction rats with chronic heart
failure[45]. Chronic AC3174 treatment also attenuated
salt-induced hypertension, cardiac morbidity, insulin
resistance, and renal dysfunction and improved survival
in Dahl salt-sensitive rats[46]. In addition, GLP-1 has an
antiapoptotic effect on b-cells during oxidative stress
probably via blocking the c-Jun-N-terminal kinase (JNK)
and glycogen synthasekinase 3b (GSK3b)m e d i a t e d
apoptotic pathway[47]. So far, GLP-1 and its analogs are
only available as injectable dosage forms. Recently, a sin-
gle dose of the exenatide-based ORMD-0901 formula-
tion was enterically delivered to pigs and beagle canines
[48]. The results show that enterically delivered ORMD-
0901 was well tolerated by the animals and that GLP-1
(ORMD-0901) was absorbed from the gastrointestinal
tracts and retained its biological activity. Hence, devel-
opment of this drug class in an oral dosage form has
the potential to enhance diabetes control and patient
compliance.
Conclusions
O u rd a t ad e m o n s t r a t ef o rt h ef i r s tt i m et h a tG L P - 1( 7 -
36 amide) can enhance voltage-gated L-type Ca
2+ cur-
rents in cardiomyocytes and such enhancement may
contribute to the prolongation of APs. These effects are
most likely via the activation of the cardiac GLP-1R and
then the cAMP-dependent PKA pathway. These findings
suggest a novel mechanism of the potential beneficial
cardiac effects of GLP-1R agonists on the improvement
of myocardial contractility.
Abbreviations
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